Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension

Pulmonary Pharmacology and Therapeutics

Volumn 10, Issue 5-6, 1997, Pages 231-241

  Voelkel, Norbert F ^a   Tuder, Rubin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CYCLIC GMP; CYTOCHROME P450; ENDOTHELIN; HEPARIN; MATRIX PROTEIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; POTASSIUM CHANNEL; PROTEIN KINASE C; SEROTONIN; SOMATOMEDIN; TROPOELASTIN; VASCULOTROPIN;

ANGIOGENESIS; ARTERY TONE; ARTERY WALL; CELL GROWTH; CYTOLOGY; GENE THERAPY; HUMAN; HYPERPLASIA; LUNG CIRCULATION; LUNG VASOCONSTRICTION; MITOCHONDRION; MOLECULAR BIOLOGY; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0031260620     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0100     Document Type: Review

References (104)

1. 1. Voelkel N F, Tuder R M. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
2. 2. Madden J A, Vadula M S, Kurup V P. Effects of hypoxia and other vasoactive agents on pulmonary and cerebral artery smooth muscle cells. Am J Physiol 1992; 263 (Lung Cell Mol Physiol, 7): L384-L393.
3. 3. Murray T R, Marshall B E, Macarak E J. Contraction of vascular smooth muscle in cell culture. J Cell Physiol 1990; 143: 26-38.
4. 4. Murray T R, Chen L, Marshall B E, Macarak E J. Hypoxic contraction of cultured pulmonary vascular smooth muscle cells. Am J Respir Cell Mol Biol 1990; 3: 457-465.
5. 5. Post J, Hume J, Archer S, Weir E. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 1992; 262: C882-890.
6. + channels in canine pulmonary artery: novel mechanism for hypoxia-induced membrane depolarization. Circ Res 1995; 77: 131-139.
7. 7. Weir E K, Archer S L. The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J 1995; 9: 183-189.
8. 8. Yuan X-J, Goldman W, Tod M, Rubin L, Blaustein M. Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol 1993; 264: L116-123.
9. 9. Archer S L, Huang J M C, Hampl V, Nelson D P, Shultz P J, Weir E K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994; 91: 7583-7587.
10. 10. Buckler K J. A novel oxygen-sensitive potassium current in rat carotid body type I cells. J Physiol 1997; 498.3: 649-662.
11. 11. Peng W, Karwande S V, Hoidal J R, Farrukh I S. Potassium currents in cultured human pulmonary arterial smooth muscle cells. J Appl Physiol 1996; 80(4): 1187-1996.
12. 12. Yuan X-J. Role of calcium-activated chloride current in regulating pulmonary vasomotor tone. Am J Physiol 1997; 272 (Lung Cell Mol Physiol 16): L959-L968.
13. 13. Archer S L, Huang J M C, Reeve H L, et al. The differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Circ Res 1996; 78: 431-442.
14. + channel distribution in smooth muscle cells isolated from the pulmonary arterial tree of the rat. Biochem Biophys Res Commun 1995; 208: 183-189.
15. 15. Lippton H L, Hauth T Z, Summer W R, Hyman A L. Endothelin produces pulmonary vasoconstriction and systemic vasodilation. J Appl Physiol 1989; 66: 1008-1012.
16. 16. Hasunuma K, Rodman D M, O'Brien R F, McMurtry I F. Endothelin 1 causes pulmonary vasodilation in rats. Am J Physiol 1990; 259: H48-54.
17. 17. Rounds S, McMurtry I F. Inhibitors of oxidative ATP production cause transient vasoconstriction and block subsequent pressor responses in rat lungs. Circ Res 1981; 48: 393-400.
18. 18. Stanbrook H S, McMurtry I F. Inhibition of glycolysis potentiates hypoxic vasoconstriction in rat lungs. Am Physiol Soc 1983; 55: 1467-1473.
19. 19. Voelkel N F. Regulation of pulmonary vascular tone. Eur Respir Rev 1993; 3: 16543-16549.
20. 20. Rigoulet M, Ouhabi R, Leverve X, Putod-Paramelle F, Guerin B. Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta 1989; 975: 325-329.
21. 21. Geng Y J, Hansson G K, Holme E. Interferon-γ and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992; 71: 1268-1276.
22. 2 sensor in rat pulmonary vasculature. Circ Res 1993; 73: 1100-1112.
23. V currents in pulmonary artery myocytes. Am J Physiol 1996; 270 (Cell Physiol 39): C321-C331.
24. 24. Andoh Y, Shimura S, Aikawa T, Sasaki H, Takishima T. Perivascular fibrosis of muscular pulmonary arteries in chronic obstructive pulmonary disease. Chest 1992; 102: 1645-1649.
25. 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
26. 26. Scott-Burden T, Buhler F R. Regulation of smooth muscle proliferative phenotype by heparinoid-matrix interactions. Am J Cardiol 1988; 9: 94-98.
27. 27. Stouffer G A, Owens G K. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β. Circ Res 1992; 70: 820-828.
28. 28. Stouffer G A, Owens G K. TGF-beta promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-independent mechanisms. J Clin Invest 1994; 93: 2048-2055.
29. 29. Stouffer G A, Shimizu R T, Turla M B, Owens G K. ANG II- or AVP-induced increases in protein synthesis are not dependent on autocrine secretion of PDGF-AA. Am J Physiol 1993; 264: C390-C395.
30. 30. Gadeau A P, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arteriosclerosis and Thrombosis 1993; 13: 120-125.
31. 31. Rothman A, Wolner B, Button D, Taylor P. Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells. J Biol Chem 1994; 269: 6399-6404.
32. 32. Rodan G A. Osteopontin overview. Ann NY Acad Sci 1995; 760: 1-5.
33. 33. Denhardt D T, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-1482.
34. 34. Murry C E, Gipaya C T, Bartosek T, Benditt E P, Schwartz S M. Monoclonality of smooth muscle cells in human atherosclerosis. Amer J Path 1997; 151: 697-705.
35. 35. DeRuiter M C, Poelmann R E, VanMunsteren J C, Mironov V, Markwald R R, Gittenberger-deGroot A C. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res 1997; 80: 444-451.
36. 36. Arciniegas E, Sutton A B, Alled T D, Schor A M. Transforming growth factor beta-a promoted the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci 1992; 103: 521-529.
37. 37. Gorski D H, Walsh K. Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Cardiovas Res 1995; 30: 585-592.
38. 38. Mecham R P, Whitehouse L A, Wrenn D S, Parks W C, Griffin G L, Senior R M, Crouch E C, Stenmark K R, Voelkel N F. Smooth muscle-mediated connective tissue remodeling in pulmonary hypertension. Science 1987; 237: 423-426.
39. 39. Todorovich-Hunter L, Johnson D J, Ranger P, Keeley F W, Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. Lab Invest 1988; 58: 184-195.
40. 40. Frid N G, Moiseeva E P, Stenmark K R. Multiple phenotypically distinct smooth muscle cell populations exist in the adult and developing bovine pulmonary arterial media in vivo. Circ Res 1994; 75: 669-681.
41. 41. Wohrley J D, Frid M G, Moiseeva E P, Orton E C, Belknap J K, Stenmark K R. Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media. J Clin Invest 1995; 96: 273-281.
42. 42. Stenmark K R, Durmowicz A G, Roby J, Mecham R P, Parks W C. Persistence of the fetal pattern of tropoelastin expression in hypoxic pulmonary hypertension. J Clin Invest 1993; 93: 1234-1242.
43. 43. Cool C, Voelkel N F, Tuder R M. Three-dimensional reconstruction of the plexiform lesions in pulmonary hypertension. Am J Respir Crit Care Med 1996; 153: A40.
44. 44. Durmowicz A, Frid M, Wohrley J, Stenmark K. Expression and localization of tropoelastin mRNA in the developing bovine pulmonary artery is dependent on vascular cell phenotype. Am J Respir Cell Mol Biol 1996; 14: 569-576.
45. 45. Prosser I W, Stenmark K R, Suthar M, Crouch E C, Mecham R P, Parks W C. Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization. Am J Pathol 1989; 135: 1073-1088.
46. 46. Herren B, Raines E, Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 1997; 11: 173-180.
47. 47. Newby A C, Southgate K M, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of atherosclerosis. Basic Res Cardiol 1994; 89: 59-70.
48. 48. Jongeneel C V, Bouvier J, Bairoch A. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 1989; 242: 211-214.
49. 49. Botney M. Vascular remodeling in primary pulmonary hypertension: what role for transforming growth factor-beta. Semin Respir Crit Care Med 1994; 15: 215-225.
50. 50. Poiani G J, Tozzi C A, Thakker-Varia S, Choe J K, Riley D J. Effect of glucocorticoids on collagen accumulation in pulmonary vascular remodeling in the rat. Am J Respir Crit Care Med 1994; 149: 994-999.
51. 51. Tozzi C A, Christiansen D L, Poiani G J, Riley D J. Excess collagen in hypertensive pulmonary arteries decreases vascular distensibility. Am J Respir Crit Care Med 1994; 149: 1317-1326.
52. 2+-oscillations in vascular myocytes from the rat pulmonary artery. A J Physiol 1996; 270 (Lung Cell Mol Physiol 14): L637-L642.
53. 53. Weber H, Taylor D S, Molloy C J. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells: correlation with the expression of specific endogenous growth factors and reversal by Suramin. J Clin Invest 1994; 93: 788-798.
54. 54. Morrell N W, Atochina E N, Morris K G, Danilov S M, Stenmark K R. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 1995; 96: 1823-1833.
55. 55. Morrell N W, Grieshaber S S, Danilov S M, Majack R A, Stenmark K R. Developmental regulation of angiotensin converting enzyme and angiotensin type 1 receptor in the rat pulmonary circulation. Am J Respir Cell Mol Biol 1996; 14: 526-537.
56. 56. Gibbons G H, Dzau V J. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension. Cardiovasc Drug Ther 1990; 4: 237-242.
57. 57. Powell J S, Clozel J P, Muller R K M, Kuhn H, Hefti F, Hosang M, Baumgartner H R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (Wash, DC) 1989; 245: 186-188.
58. 58. Zakheim R M, Mattioli L, Molteni A, Mullis K B, Bartley J. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin-I converting enzyme in the rat. Lab Invest 1975; 33(1): 57-61.
59. 59. Molteni A, Ward W F, Ts'ao C-H, Solliday N H. Monocrotaline-induced cardiopulmonary damage in rats: Amelioration by the angiotensin-converting enzyme inhibitor CL242817 (42370). Proc Soc Exp Biol Med 1986; 182: 483-493.
60. 60. Abraham W, Raynolds M, Gottschall B, Badesch D, Wynne K, Groves B, Lowes B, Bristow M, Perryman M, Voelkel N. Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 1995; 86 (Suppl 1): 9-15.
61. 61. Lee S-L, Wang W W, Lanzillo J J, Fanburg B L. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266 (Lung Cell Mol Physiol 10): L46-L52.
62. 62. Lee S-L, Wang W W, Fanburg B L. Nitroprusside inhibits serotonin-induced mitogenesis and tyrosine phosphorylation of smooth muscle cells. Am J Physiol 1996; 270 (Lung Cell Mol Physiol 14): L362-L367.
63. 63. Pitt B R, Weng W, Steve A R, Blakely R D, Reynolds I, Davies P. Serotonin increase DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am J Physiol 1994; 266 (Lung Cell Mol Physiol 10): L178-L186.
64. 64. McGoon M D, Vanhoutte P M. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984; 74: 828-833.
65. 65. Fanburg B L, Lee S-L. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997; 272: L795-L806.
66. 66. Herve P, Launay J-M, Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Curoux P, Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Amer J Med 1995; 99: 249-254.
67. 67. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
68. 68. Bornfeldt K E, Raines E W, Nakano T, Graves L M, Krebs E G, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994; 93: 1266-1274.
69. 69. Badesch D B, Lee P D K, Parks W C, Stenmark K R. Insulin-like growth factor I stimulates elastin synthesis by bovine pulmonary arterial smooth muscle cells. Biochem Biophys Res Commun 1989; 160: 382-387.
70. 70. Perkett E A, Badesch D B, Roessler M K, Stenmark K R, Meyrick B. Insulin-like growth factor 1 and pulmonary hypertension induced by continuous air embolization in sheep. Am J Respir Cell Mol Biol 1992; 6: 82-87.
71. 71. Dempsey E C, Stenmark K R, McMurtry I F, O'Brien R F, Voelkel N F, Badesch D B. Insulin-like growth factor I and protein kinase C activation stimulate pulmonary artery smooth muscle cell proliferation through separate but synergistic pathways. J Cell Physiol 1990; 144: 159-165.
72. 72. Dempsey E C, McMurtry I F, O'Brien R F. Protein kinase C-activation allows pulmonary artery smooth muscle cells to proliferate to hypoxia. Am J Physiol 1991; 260 (Lung Cell Mol Physiol 4): L136-L145.
73. 73. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
74. 74. Jakeman L B, Winer J, Bennett G L, Altar C A, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992; 89: 244-253.
75. 75. Monacci W T, Merril M J, Oldfield E H. Expression of vascular permeability factor/vascular endothelial permeability/growth factor in normal rat tissues. Am J Physiol 1993; 254: C995-C1002.
76. 76. Liu X, Cox S R, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: Identification of a 5′ enhancer. Circ Res 1995; 77: 638-643.
77. 77. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94: 1647-1654.
78. 78. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26955.
79. 79. Höper M M, Voelkel N F, Bates T O, Allard J D, Horan M, Shepherd D, Tuder R M. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17: 748-756.
80. 3 integrin, osteopontin and thrombin. Am J Pathol 1996; 149: 293-305.
81. 81. Dempsey E C, Fasules J, Orton E C, Mecham R P, Das M, Stenmark K. Heparin attenuates severe pulmonary vascular remodeling in hypoxia-exposed neonatal calves: in vivo and in vitro effects. Am Rev Respir Dis 1995; 151: A733.
82. 82. Castellot J J, Cochran D L, Karnovsky M J. Effect of heparin on vascular smooth muscle cells. I Cell metabolism. J Cell Physiol 1985; 124: 21-28.
83. 1 phase of the cell cycle. J Biol Chem 1989; 264: 6990-6995.
84. 84. Simons M, Edelman E R, DeKeyser J-L, Langer R, Rosenberg R D. Antisense c-myb oligonucleotides inhibit intimai smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
85. 85. Rosenberg R D. Vascular smooth muscle cell proliferation: basic investigations and new therapeutic approaches. Thrombosis and Haemostasis 1993; 70(1): 10-16.
86. 86. Silverman E S, Goslant C E, Quinn D A, Bonventre J V, Joseph P M, Thompson B T, Hales C A. A comparison of Na+/H+ exchange in human pulmonary artery smooth muscle cells and human aortic smooth muscle cells. Am Rev Respir Dis 1994; 149: A294.
87. 87. Moncada S, Palmer R M J, Higgs E A. NO: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
88. 88. Garg U C, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
89. 89. Yu S-M, Hung L-M, Lin C-C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997; 95: 1269-1277.
90. 90. Chinkers M, Garbers D L, Chang M-S, Lowe D G, Chin H, Goeddel D V, Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989; 338: 78-83.
91. 91. Li H, Oparil S, Meng Q C, Elton T S, Chen Y-F. Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia. Am J Physiol 1995; 268 (Lung Cell Mol Physiol 12): L328-L335.
92. 92. Hill N S, Klinger J R, Warburton R R, Pietras L, Wrenn D S. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 1994; 266 (Lung Cell Mol Physiol 10): L308-L315.
93. 93. Sherr C J. Cancer cell cycles. Science 1996; 274: 1672.
94. 94. Nasmyth K. Putting the cell cycle in order. Science 1996; 274: 1643.
95. 95. Ferns G A, Raines E W, Sprugel K H, Motani A S, Reidy M A, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody of PDGF. Science 1991; 253: 1129-1132.
96. 96. Morishita R, Gibbons G H, Ellison K E, Nakajima M, von der Leyen H, Shang L, Kaneda Y, Ogihara T, Dzau V J. Intimal hyperplasia after vascular injury in inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-1464.
97. 97. Morishita R, Gibbons G H, Horiuchi M, Ellison K E, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau V J. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
98. 98. Mann J R, Gibbons G H, Kernoff R S, Diet F P, Tsao P S, Cooke J P, Kaneda Y, Dzau V J. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995; 92: 4502-4506.
99. 99. Folkman J, D'Amore P A. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-1155.
100. 100. Suri C, Jones P F, Patan S, Bartunkova S, Maisonpierre P C, Davis S, Sato T N, Yancopoulos G D. Requisite role of angiopoietin-1, a ligand for the TIE-2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180.
101. 101. Vikkula M, Boon L M, Carraway K L, Calvert J T, Diamonti A J, Goumnerov B, Pasyk K A, Marchuk D A, Warman M L, Cantley L C, Mulliken J P, Olsen B R. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87: 1181-1190.
102. 102. Oliva D, Noe A, Nicosia S, Bernini F, Fumagalli R, Whittle B, Moncada S, Vane J. Prostacyclin-sensitive adenylate cyclase in cultured myocytes: differences between rabbit aorta and mesenteric artery. Eur J Pharm 1984; 105: 207-213.
103. 2 for platelet-derived growth factor signal transduction. Science 1995; 270: 296-299.
104. 104. Ziche M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger H J, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-2634.